Cargando…
The effect of physical activity on cognition relative to APOE genotype (PAAD-2): study protocol for a phase II randomized control trial
BACKGROUND: By 2050, the prevalence of Alzheimer’s disease (AD) in the United States is predicted to reach 13.8 million. Despite worldwide research efforts, a cure for AD has not been identified. Thus, it is critical to identify preventive strategies that can reduce the risk of or delay the onset of...
Autores principales: | Park, Kyoung Shin, Ganesh, Alexis B., Berry, Nathaniel T., Mobley, Yashonda P., Karper, William B., Labban, Jeffrey D., Wahlheim, Christopher N., Williams, Tomika M., Wideman, Laurie, Etnier, Jennifer L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274941/ https://www.ncbi.nlm.nih.gov/pubmed/32503473 http://dx.doi.org/10.1186/s12883-020-01732-1 |
Ejemplares similares
-
An innovative protocol for the artificial speech-directed, contactless administration of laboratory-based comprehensive cognitive assessments: PAAD-2 trial management during the COVID-19 pandemic
por: Park, K. Shin, et al.
Publicado: (2021) -
An External Focus of Attention is Effective for Balance Control when Sleep-deprived
por: DIEKFUSS, JED A., et al.
Publicado: (2018) -
PEX13 is a potential immunotherapeutic indicator and prognostic biomarker for various tumors including PAAD
por: Dong, Penggang, et al.
Publicado: (2023) -
Cuprotosis Programmed-Cell-Death-Related lncRNA Signature Predicts Prognosis and Immune Landscape in PAAD Patients
por: Chi, Hao, et al.
Publicado: (2022) -
Developing and validating a survival prediction model based on blood exosomal ceRNA network in patients with PAAD
por: Wang, Shanshan, et al.
Publicado: (2022)